APPLICATION IMMUNOHISTOCHEMICALLY RESEARCH METHODS IN THE DIAGNOSIS OF PROSTATE CANCER

Introduction. The actual problem of modern urology remains differential diagnostics of various diseases of the prostate gland. The purpose of the study. Increasing the effectiveness of differential diagnosis of diseases of the prostate. Materials and methods. In the biopsy specimens of patients with benign prostatic hyperplasia (BPH) and prostate cancer (PCa), an immunohistochemical study of the production of the Ki-67 proliferation marker, matrix metalloproteinase-9, the matrix metalloproteinase inhibitor TIMP-1, and the distribution of collagen type IV was performed. Results. A moderate positive correlation was found between Gleason gradation and the cell proliferation index for Ki 67 (rs = 0.674) and a moderate negative correlation of Gleason gradation with the level of production of matrix metalloproteinase-9 (rs = -0.660). A weak significant negative correlation was established between the level of proliferative cell activity and the production of  MMP-9 tumor cells (rs = -0.369). A significant decrease in the level of MMP-9 and TIMP-1 in adenocarcinoma of different grades was revealed. The invasive properties of tumor cells, expressed in the destruction of collagen of the IV type of the basal membrane and connective tissue prostatic stroma, are mediated by the imbalance between MMP-9 and the protein blocking this enzyme - TIMP-1, whose production decreases in adenocarcinomas of different grades compared with BPH. Conclusions: 1. BPH is characterized by high production of MMP-9 type, which destroys the collagen of the basal membranes and stroma, the proteolytic action of which is blocked by the high content of TIMP-1.

denocarcinoma of the prostate, MMP-9, TIMP-1, Ki-67, IV collagen

1. Malignant neoplasms in Russia in 2015 (morbidity and mortality). Ed. Caprin AD, Starinsky VV, Petrova GV. 2017;11-15. (in Russ.)

2. Alyaev YG, Krupinov G.E, Amosov AB. Prostate cancer and HIFU therapy.Urology. 2007;(6):32-38. (in Russ.)

3. Kushlinsky NE. Molecular and cellular markers of prolifera on, diff eren a on, metastasis and neoangiogenesis in prostate cancer. Selected chapters of geriatric urology. Newmediamed. 2000; 227-273. (in Russ.)

4. Berezin AE. Regulators of the ac vity of matrix metalloproteinases as new biological markers of cardiovascular remodeling: a review of the literature. Ukrainian medical journal. 2011;(1):36-43. (in Russ.)

5. Brehmer B, Biesterfeld S, Jakse G. Expression of matrix metalloproteinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer ssue. Prostate Cancer Prosta c Dis. 2003;6:217-222. doi:10.1038/ sj.pcan.4500657

6. Gouyer V, Con M, Devos P, Zerimech F, Copin MC, Créme E, Wurtz A, Porte H, Huet G. Tissue inhibitor of metalloproteinase-1 is an independent predictor of prognosis in pa ents with non-small cell lung carcinoma who undergo resec on with cura ve intent. Cancer. 2005;(103):16761684. doi:10.1002/cncr.20965

7. Rubio J, Ramos D, López-Guerrero JA, Iborra I, Collado A, Solsona E, Almenar S, Llombart-Bosch A. Immunohistochemical expression of ki-67 antigen, cox2 and bax/bcl-2 in prostate cancer; prognostic value in biopsies and radical prostatectomy specimens. Eur. Urol. 2005;48(5):745-751. doi:10.1016/j.eururo.2005.06.014

8. Avdoshin VP, Babichenko AI, Kotelnikova EV. Prognostic value of the expression of immunohistochemical markers Ki 67, MMP 9 and collagen IV in patients with papillary urothelial cancer of the bladder. Oncourology. 2011;(3):66-70. (in Russ.)

9. Schnoor M. Production of type VI collagen by human macrophages: a new dimension in macrophage functional heterogeneity. J Immunol. 2008;(180):5707– 19. doi:10.4049/jimmunol.180.8.5707